sellWeak cluster of 3
Benjamin L Palleiko sold $119k of KALV
CHIEF EXECUTIVE OFFICER at KalVista Pharmaceuticals, Inc.. 9,999 shares at an average of $11.88, traded May 22, 2025, filed May 23, 2025.
Warning score
35Value
$119k
9,999 shares
Holdings after
306,618
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +10Trade size$119k at market
- 0Share of holdings soldSold 3.2% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-014474, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 21, 2025 | MOption exercise Common Stock | +23,250 | - | - | 316,617 | May 23, 2025 |
| May 22, 2025 | SOpen-market sale Common Stock | -9,999 | $11.88 | $119k | 306,618 | May 23, 2025 |
| May 21, 2025 | MOption exercise Restricted Stock Unitderivative | -23,250 | $0.00 | $0 | 348,750 | May 23, 2025 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $120k 7,294 shares | -2% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $51k 3,813 shares | -9% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $71k 5,296 shares | -4% | |
| 36Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $147k 10,940 shares | -3% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $58k 4,331 shares | -2% | |
| 39Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $60k 4,471 shares | -30% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $45k 3,075 shares | -2% | |
| 33Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $65k 4,466 shares | -1% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $39k 2,683 shares | -2% | |
| 31Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $38k 3,328 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.